Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
Dupilumab reduces depressive symptoms and fatigue in AD, registry study finds
9+ hour, 55+ min ago (674+ words) Depressive symptoms and fatigue improved over 12 months of dupilumab treatment among adults with moderate-to-severe atopic dermatitis (AD) in a German registry study, although the uncontrolled design prevents the changes from being attributed solely to treatment. Published in the journal Acta…...
State House hearing spotlights diversity in clinical trials
2+ hour, 9+ min ago (365+ words) A hearing was held at the Massachusetts State House on Wednesday about a gene therapy that could help save lives. The hearing was filled with medical professionals and lawmakers trying to move the needle on diversity and inclusion in clinical…...
Vortioxetine Improves Depression, Shows Mixed Cognitive Effects in Older Adults
9+ hour, 32+ min ago (288+ words) Vortioxetine was consistently associated with reduced depressive symptoms in older adults with MDD, while its effects on cognition were less consistent, according to a systematic review published in the Journal of Affective Disorders. Findings suggested neutral-to-positive effects on cognition that…...
Digital Twins For Clinical Trial Protocols: From Protocol Design To Predictive Study Execution
8+ hour, 23+ min ago (207+ words) Digital Twins For Clinical Trial Protocols From Protocol Design To Predictive Study Execution Clinical Leader Digital Twins For Clinical Trial Protocols: From Protocol Design To Predictive Study Execution By Luca Parisi, Director of Data Science; Bianca De Blasi, Lead Data…...
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
14+ hour, 34+ min ago (459+ words) Sep 23, 2026, 10:37 ET MISSISSAUGA, ON, Sept. 23, 2026 /CNW/ -- Novo Nordisk this week announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo's next innovation in weight management and type 2 diabetes. The…...
Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen
19+ hour, 8+ min ago (353+ words) The trial is to assess an investigational therapy, ulefnersen, to treat people with a genetic form of amyotrophic lateral sclerosis (ALS) known as fused-in sarcoma (FUS)-ALS. The randomised, global, multi-centre, placebo-controlled, double-blind trial, conducted in participants diagnosed with FUS-ALS,…...
Connect with emerging health science
13+ hour, 8+ min ago (55+ words) Springfield Herald News Connect with emerging health science Communities and healthcare professionals need trusted connections to stay informed of emerging advancements in health sciences. Gain research-based insights into complex health issues as researchers from University of Illinois deliver forward-thinking, holistic…...
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
19+ hour, 11+ min ago (647+ words) PR Newswire - Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. - The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk....
National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting
1+ day, 1+ hour ago (0+ words) ...
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
21+ hour, 7+ min ago (374+ words) Posted by Michael Walen on Sep 23rd, 2026 Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key…...